130 related articles for article (PubMed ID: 32998446)
1. Granzyme B Degraded Type IV Collagen Products in Serum Identify Melanoma Patients Responding to Immune Checkpoint Blockade.
Jensen C; Sinkeviciute D; Madsen DH; Önnerfjord P; Hansen M; Schmidt H; Karsdal MA; Svane IM; Willumsen N
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 32998446
[TBL] [Abstract][Full Text] [Related]
2. Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma.
Hurkmans DP; Jensen C; Koolen SLW; Aerts J; Karsdal MA; Mathijssen RHJ; Willumsen N
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093157
[TBL] [Abstract][Full Text] [Related]
3. Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients.
Jensen C; Madsen DH; Hansen M; Schmidt H; Svane IM; Karsdal MA; Willumsen N
J Immunother Cancer; 2018 Dec; 6(1):152. PubMed ID: 30567561
[TBL] [Abstract][Full Text] [Related]
4. Blood-based tumor fibrosis markers as diagnostic and prognostic biomarkers in patients with biliary tract cancer.
Christensen TD; Jensen C; Larsen O; Leerhøy B; Hansen CP; Madsen K; Høgdall D; Karsdal MA; Chen IM; Nielsen D; Johansen JS; Willumsen N
Int J Cancer; 2023 Mar; 152(5):1036-1049. PubMed ID: 36455598
[TBL] [Abstract][Full Text] [Related]
5. Serological Biomarkers of Intestinal Collagen Turnover Identify Early Response to Infliximab Therapy in Patients With Crohn's Disease.
Alexdottir MS; Bourgonje AR; Karsdal MA; Pehrsson M; Loveikyte R; van Dullemen HM; Visschedijk MC; Festen EAM; Weersma RK; Faber KN; Dijkstra G; Mortensen JH
Front Med (Lausanne); 2022; 9():933872. PubMed ID: 35903311
[TBL] [Abstract][Full Text] [Related]
6. Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohn's disease.
Bourgonje AR; Alexdottir MS; Otten AT; Loveikyte R; Bay-Jensen AC; Pehrsson M; van Dullemen HM; Visschedijk MC; Festen EAM; Weersma RK; Karsdal MA; Faber KN; Mortensen JH; Dijkstra G
Aliment Pharmacol Ther; 2022 Aug; 56(4):675-693. PubMed ID: 35661188
[TBL] [Abstract][Full Text] [Related]
7. The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety.
Wu Y; Shi H; Jiang M; Qiu M; Jia K; Cao T; Shang Y; Shi L; Jiang K; Wu H
Int J Cancer; 2017 Dec; 141(12):2562-2570. PubMed ID: 28833119
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
9. High turnover of extracellular matrix reflected by specific protein fragments measured in serum is associated with poor outcomes in two metastatic breast cancer cohorts.
Lipton A; Leitzel K; Ali SM; Polimera HV; Nagabhairu V; Marks E; Richardson AE; Krecko L; Ali A; Koestler W; Esteva FJ; Leeming DJ; Karsdal MA; Willumsen N
Int J Cancer; 2018 Dec; 143(11):3027-3034. PubMed ID: 29923614
[TBL] [Abstract][Full Text] [Related]
10. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
11. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
[TBL] [Abstract][Full Text] [Related]
12. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
13. Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study.
Khattak MA; Abed A; Reid AL; McEvoy AC; Millward M; Ziman M; Gray ES
Front Oncol; 2020; 10():1041. PubMed ID: 32695680
[No Abstract] [Full Text] [Related]
14. Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional
Da Gama Duarte J; Parakh S; Andrews MC; Woods K; Pasam A; Tutuka C; Ostrouska S; Blackburn JM; Behren A; Cebon J
Front Immunol; 2018; 9():411. PubMed ID: 29552014
[TBL] [Abstract][Full Text] [Related]
15. High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients.
Chakravarti N; Ivan D; Trinh VA; Glitza IC; Curry JL; Torres-Cabala C; Tetzlaff MT; Bassett RL; Prieto VG; Hwu WJ
Melanoma Res; 2017 Feb; 27(1):24-31. PubMed ID: 27768639
[TBL] [Abstract][Full Text] [Related]
16.
Ito K; Teng R; Schöder H; Humm JL; Ni A; Michaud L; Nakajima R; Yamashita R; Wolchok JD; Weber WA
J Nucl Med; 2019 Mar; 60(3):335-341. PubMed ID: 30413661
[TBL] [Abstract][Full Text] [Related]
17. Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response.
Larimer BM; Wehrenberg-Klee E; Dubois F; Mehta A; Kalomeris T; Flaherty K; Boland G; Mahmood U
Cancer Res; 2017 May; 77(9):2318-2327. PubMed ID: 28461564
[TBL] [Abstract][Full Text] [Related]
18. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
19.
Wong A; Callahan J; Keyaerts M; Neyns B; Mangana J; Aberle S; Herschtal A; Fullerton S; Milne D; Iravani A; McArthur GA; Hicks RJ
Cancer Imaging; 2020 May; 20(1):36. PubMed ID: 32408884
[TBL] [Abstract][Full Text] [Related]
20. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters.
Nielsen MJ; Nedergaard AF; Sun S; Veidal SS; Larsen L; Zheng Q; Suetta C; Henriksen K; Christiansen C; Karsdal MA; Leeming DJ
Am J Transl Res; 2013; 5(3):303-15. PubMed ID: 23634241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
